Skip to main content
Equibles

4552 · JCR Pharmaceuticals Co.,Ltd. · Financials

Use 4552 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4552.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
Rebalance outlook locked

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
40.32B +21.9%
FY2026 Revenue FY2025–FY2026
Net Income
2.18B +148.8%
FY2026 Net Income FY2025–FY2026
Gross Margin
74.87% +7.8pp
FY2026 Gross Margin FY2025–FY2026
Operating Margin
1.38% +20.2pp
FY2026 Operating Margin FY2025–FY2026
Operating Cash Flow
-135M +97.7%
FY2026 Operating Cash Flow FY2025–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025
JPY 40.32B 33.07B
JPY 10.13B 10.9B
JPY 30.19B 22.17B
JPY 555M -6.22B
JPY 3.22B -5.98B
JPY 1.02B -1.59B
JPY 2.18B -4.46B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2025–FY2026: 4.95B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.